



Eurofins continues Asia Pacific expansion with the acquisition of mgt-LabMark in Australia and ELS in New Zealand

22 January 2013

Eurofins Scientific (EUFI.PA), the global leader in food, environment and pharmaceutical product testing services, announces the acquisition of an 80% majority stake in mgt-LabMark, the largest private environmental testing laboratory network in Australia. The Group also recently acquired ELS Ltd (ELS), a food and environmental testing laboratory in New Zealand.

mgt-LabMark, founded in 1975, generated revenues of about EUR 20m in 2012, and employs over 200 staff in 3 laboratories and 4 satellite offices strategically located across Australia. As an integrated environmental testing service provider, mgt-LabMark provides a comprehensive range of analytical services for water, air and soil to the largest industrial companies and environmental consultants throughout the country. This acquisition provides Eurofins an entry into the attractive Australian market, and a strong platform to roll-out a broader service offering, including expansion into the domestic food testing market.

In New Zealand, ELS reinforces Eurofins' presence in the country following its acquisition of NZ Labs in June 2012. ELS operates a large laboratory in the Wellington area with 50 staff. ELS represents an excellent operational and geographical fit with the Group's existing activities in the local market. It reinforces Eurofins' growing presence in the food testing market, and extends the Group's footprint into the environmental testing market. Furthermore, it is strategically located between Auckland and Christchurch, strengthening Eurofins' presence in New Zealand's largest cities.

Australia and New Zealand, both with substantial food and agricultural sectors, represent an attractive market given the presence of many of the large, global food producers in the region. In addition, both countries have active environmental testing markets given the vast natural resources, and large minerals sectors.

Comment from Gilles Martin, Eurofins CEO: *"The acquisition of mgt-LabMark in Australia and ELS in New Zealand demonstrates our commitment to develop a strong presence in the Asia Pacific region. Both companies provide an excellent strategic fit to Eurofins' growing operations, and should allow us to accelerate our expansion in the region, having already strengthened our position in Japan with the acquisition of Nihon Kankyo in 2012. We look forward to further strengthening their position in their respective markets by offering the full range of capabilities of the Group."*

For more information, please visit www.eurofins.com or contact:

Eurofins Investor Relations
Phone: +32-2-766 1620
E-mail: ir@eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agrosience, genomics and central laboratory services.

With over 13,000 staff in more than 170 laboratories across 33 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results in time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.